XenoPort, Inc. Overview

State:California
Country:United States
Industry:Biotechnology and Drugs
Description:
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates, which utilizes the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. The product candidates referred to as Transported Prodrugs are created by modifying the chemical structure of marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and/or metabolism of the parent drug. The product candidate, XP13512 (gabapentin enacarbil), is licensed to Astellas Pharma Inc. in Japan and five Asian countries and to Glaxo Group Limited (GSK), in the United States and all other regions globally. Horizant has completed the Phase II clinical trials for management of... (More)

Get Trial Access to OneSource

Company profiles, executive contacts, industry research, and news for sales, marketing and research professionals.

Disclaimer: While the OneSource Subscription Service maintains the freshest, most accurate data possible, this free site is refreshed on a periodic basis and may occasionally contain information that is not current. If you would like to alert us to a change, please email us, and we will take steps to make sure your update is included as soon as possible

XenoPort, Inc. Overview

Get Trial Access to OneSource

Business Information

Executive Profiles

Company Lists